Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2018

Filing Date
Filed February 8, 2019
Period End
December 31, 2018
Security
NBIX
One revenue dollarkept$0.05
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Oct ’17Oct ’17
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 8, 2019. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported 2018 total revenues of $451.2 milliona, up from $161.6 million in 2017, driven primarily by INGREZZA net product sales of $409.6 million (versus $116.6 million in 2017).

The company reported net income of $21.1 millionb, or $0.22 per diluted share, compared with a net loss of $142.5 million in 2017. Collaboration revenue was $41.6 million in 2018, including a $40 million event-based milestone from AbbVie upon FDA approval of ORILISSA for endometriosis pain. Total operating expenses rose to $414.3 million, with SG&A of $248.9 million and R&D of $160.5 million, reflecting the INGREZZA commercial launch and pipeline progression.

Cash, cash equivalents and investments totaled $866.9 millionc at year-end, against $517.5 million of 2.25% convertible senior notes due 2024. The company states that existing resources are sufficient for at least the next 12 months. The filing highlights concentration and execution risks: three customers accounted for approximately 93% of product revenue in 2018, INGREZZA relies on single-source suppliers, and the company has an accumulated deficit of approximately $1.2 billion.

Management also disclosed that T-Force GOLD, a Phase IIb study of valbenazine in pediatric Tourette syndrome, failed to meet its primary endpoint in December 2018. Subsequent to year-end, on January 28, 2019, the company agreed to a collaboration with Voyager Therapeutics involving a $115 milliond upfront cash payment and a $50 million equity purchase, with Voyager eligible for up to $1.7 billion in milestones across four gene therapy programs. Pipeline near-term catalysts described in the filing include an anticipated NDA submission for elagolix in uterine fibroids in the middle of 2019 (partnered with AbbVie), an anticipated opicapone NDA submission in the second quarter of 2019, and initial NBI-74788 Phase II results in the first quarter of 2019.

Key Highlights

  1. Total revenues of $451.2 million in 2018, up from $161.6 million in 2017; INGREZZA product sales, net, were $409.6 million, up from $116.6 million.
  2. Net income of $21.1 million ($0.22 per diluted share) in 2018, compared with a net loss of $142.5 million in 2017, marking the first year of profitability reported in the filing.
  3. Collaboration revenue of $41.6 million in 2018, including a $40 million event-based milestone from AbbVie following FDA approval of ORILISSA for endometriosis pain.
  4. Cash, cash equivalents and investments of $866.9 million at December 31, 2018, against $517.5 million principal of 2.25% convertible senior notes due May 15, 2024.
  5. Three largest customers represented approximately 93% of product revenue for 2018, and INGREZZA depends on single-source suppliers for its drug product and active pharmaceutical ingredient.
  6. T-Force GOLD Phase IIb study of valbenazine in pediatric Tourette syndrome failed to meet its primary endpoint, announced December 12, 2018.
  7. Voyager Therapeutics collaboration signed January 28, 2019, with a $115 million upfront cash payment, a $50 million stock purchase, and up to $1.7 billion in potential milestones across four gene therapy programs.

Follow one dollar

Of each $1.00 of revenue in FY2018, Neurocrine Biosciences kept $0.05.

  1. Revenue$451.2M100.0%
  2. Cost of revenue−$4.9M1.1%
  3. Gross profit$446.3M98.9%
  4. Operating costs−$409.5M90.8%
  5. Operating income$36.8M8.2%
  6. Interest, other & tax−$15.7M3.5%
  7. Net income$21.1M4.7%
Computed from 10-KFY2018filed February 8, 2019Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2018 revenue went

$451.2M
  • SG&A: $248.9M, 55% of revenue
  • R&D: $160.5M, 36% of revenue
  • Net income: $21.1M, 4.7% of revenue
  • Cost of revenue: $4.9M, 1.1% of revenue
  • Interest, other & tax: $15.7M, 3.5% of revenue

Kept 4.7% as net incomeNet income $21.1M · 4.7%

Full revenue history →

Financial Statements

FY2018 against FY2017

Line itemFY2018FY2017Change
Revenue$451.20M$161.63M+179.2%
Cost of Revenue$4.89M$1.25M+289.9%
Gross Profit$446.31M$160.37M+178.3%
R&D Expenses$160.52M$121.83M+31.8%
SG&A Expenses$248.90M$169.91M+46.5%
Operating Expenses$414.40M$292.99M+41.4%
Operating Income$36.80M-$131.36M+128.0%
Interest Expense$30.50M$19.52M+56.2%
Net Income$21.10M-$142.54M+114.8%
EPS (Basic)$0.23$-1.62+114.2%
EPS (Diluted)$0.22$-1.62+113.6%
Shares Outstanding (Basic)90.20M88.09M+2.4%
Shares Outstanding (Diluted)95.40M88.09M+8.3%

Frequently Asked Questions

  1. What drove the revenue increase in 2018?

    Total revenues rose to $451.2 million from $161.6 million. INGREZZA net product sales were $409.6 million, compared with $116.6 million in 2017, following the April 2017 FDA approval for tardive dyskinesia. Collaboration revenue was $41.6 million, including a $40 million AbbVie milestone tied to ORILISSA approval.

  2. Is the company profitable, and what are its remaining losses?

    The company reported net income of $21.1 million for 2018, versus net losses of $142.5 million in 2017 and $141.1 million in 2016. The filing states the company has an accumulated deficit of approximately $1.2 billion and that future profitability may fluctuate, with no assurance of sustained profitability.

  3. What are the main risks to INGREZZA sales?

    The filing cites a high concentration of revenue in three customers (about 93% of product revenue), reliance on single-source suppliers for INGREZZA, limited sales and marketing experience, reimbursement and pricing pressures, and competition from AUSTEDO, which Teva received approval for in August 2017 to treat TD.

  4. What is the company's liquidity position and debt obligation?

    Cash, cash equivalents and investments totaled $866.9 million at December 31, 2018. The company has $517.5 million of 2.25% convertible senior notes due May 15, 2024, and management believes existing resources and investment income will be sufficient for at least the next 12 months.

  5. What key pipeline events are expected next?

    The filing anticipates an NDA submission for elagolix in uterine fibroids in the middle of 2019 (partnered with AbbVie), an NDA submission for opicapone in the second quarter of 2019, and initial results from the NBI-74788 Phase II study in classic CAH in the first quarter of 2019.